Factor VLeiden and Prothrombin G20210A Gene Polymorphisms in Patients with Coronary Artery Disease.
10.3349/ymj.2008.49.2.237
- Author:
Bahadir ERCAN
1
;
Lulufer TAMER
;
Nehir SUCU
;
Hasan PEKDEMIR
;
Ahmet CAMSARI
;
Ugur ATIK
Author Information
1. Department of Biochemistry, Mersin University, Medical Faculty, Mersin, Turkey. lutamer@yahoo.com
- Publication Type:Original Article
- Keywords:
Coronary artery disease;
Factor VLeiden;
prothrombin G20210A gene
- MeSH:
Aged;
Coronary Artery Disease/*genetics;
Factor V/*genetics;
Female;
Gene Frequency;
Genotype;
Humans;
Male;
Middle Aged;
*Polymorphism, Single Nucleotide;
Prothrombin/*genetics
- From:Yonsei Medical Journal
2008;49(2):237-243
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: The precise molecular mechanisms culminating in coronary artery disease (CAD) are not well understood, despite a wealth of knowledge on predisposing risk factors and pathomechanisms. CAD and myocardial infarction (MI) are complex genetic diseases; neither the environment alone, nor a single gene, cause disease, rather, a mix of environmental and genetic factors lead to atherosclerosis of the coronary arteries. MATERIALS AND METHODS: In the present study, our aim was to investigate the roles of prothrombin G20210A mutation and Factor VLeiden mutation in atherosclerotic coronary artery disease. 287 subjects (106 control subjects, who were angiographically normal, and 181 angiographically documented coronary atherosclerotic patients who exhibited coronary artery narrowing to a degree of > or = 50%) were included in this study. The mutations were assessed with LightCycler Real-Time PCR mutation detection kits (Roche Diagnostics, GmbH, Germany). RESULTS: 6.6% of control subjects, and 6.1% of patients with (50% coronary artery narrowing were determined to have the Factor VLeiden heterozygote mutation. 6.6% of control subjects had the Prothrombin G20210A heterozygote mutation, while 7.7% of patients with (50% coronary artery narrowing had this mutation. The OR for Factor VLeiden was 1.52 (CI: 0.240-9.602) and for Prothrombin G20210A mutation, the OR was 1.415 (CI: 0.287-6.962). CONCLUSION: Although both the heterozygote Factor VLeiden and Prothrombin gene mutations were more frequent in patients with CAD than in control subjects, there was no statistical relationship found to exist between coronary artery disease and the Factor VLeiden and Prothrombin G20210A mutations.
